For example Krishnan et al. 9 reported that Ang1–7 administration increased the soluble fraction of soluble fms-like tyrosine kinase-1 (sFlt-1), an antagonist of VEGF and placental growth factor (PlGF), resulting in the proliferation and angiogenesis of human prostate cancer xenografts9. Here, VEGFA is linked to prostate cancer.